Results 81 to 90 of about 64,232 (120)

Effect of a fibrinolytic agent (Arvin) on wound healing and collagen formation. [PDF]

, 1970
P.J. Holt, V. Holloway, N. Raghupati, James Calnan   +3 more
openalex   +1 more source

Controversies in the Management of Ischemic Cerebrovascular Accidents in Patients With Non-Promyelocytic Acute Myeloid Leukemia. [PDF]

J Hematol
Babakhanlou R, Krishnadasan R.
europepmc   +1 more source

Targeting lipoprotein(a): Pharmacotherapy in focus. [PDF]

Eur Heart J Cardiovasc Pharmacother
Tan DS, Ooi ZH, Lew CSF.
europepmc   +1 more source

Nebulized alteplase in coronavirus disease 2019 pneumonia: a case series. [PDF]

J Med Case Rep
Milacek C, Stefan AN, Bal C, Geist M, Guttmann C, Idzko M, Antoniewicz L.   +6 more
europepmc   +1 more source

In vitro anticoagulant activity of crude fibrinolytic protease HSFT-2 as an alternative anticoagulant agent

Muhammad Ardi Afriansyah, Toeti Rahajoe, Raksi Pranindira   +2 more
openalex   +1 more source

Effects of KC-764, an anti-plate-let agent, on the coagulo-fibrinolytic system.

, 1993
Yasuhiro Mitsuoka, Tokuei Tachiiri, Y Ishibashi, Kenjiro Momo   +3 more
openalex   +1 more source

Exploiting the Molecular Properties of Fibrinogen to Control Bleeding Following Vascular Injury. [PDF]

Int J Mol Sci
Singh T, Hasan M, Gaule TG, Ajjan RA.
europepmc   +1 more source

trans-4-(Aminomethyl)cyclohexane Carboxylic Acid (T-AMCHA), an Anti-Fibrinolytic Agent, Accelerates Barrier Recovery and Prevents the Epidermal Hyperplasia Induced by Epidermal Injury in Hairless Mice and Humans

, 1997
Mitsuhiro Denda, Kenji Kitamura, Peter M. Elias, Kenneth Feingold   +3 more
openalex   +1 more source

Pharmaco-Invasive Strategy with Half-Dose Recombinant Human Prourokinase Versus Primary Percutaneous Coronary Intervention. [PDF]

Anatol J Cardiol
Jiang C, Dou J, Yang H, Guo R, Gao J, Liu B, Shu H, Hou Y, Zhao L, Guo J, Luo D.   +10 more
europepmc   +1 more source

The impact of physical activity and intensity on clot mechanical microstructure and contraction in middle-aged/older habitual runners. [PDF]

BMC Neurol
Zaldua JC, Watson O, Gregoire DJ, Pillai S, Hellsten Y, Hawkins K, Evans PA.   +6 more
europepmc   +1 more source